Other innovations
If your innovation doesn’t fit any of the active categories then this is the place to submit your innovation for feedback and the opportunity for wider adoption across the region.

Ideas (Clinical trials and evidence)

Innovation 'Elevator Pitch':
Future-proof blockchain based provenance solution for CGT. Our digital service creates an efficient & transparent chain of identity/custody/condition & diagnostic, address compliance burdens, reduce cost & enable co-operation in a competitive arena.
Overview of Innovation:
FarmaTrust have used blockchain to create a tracking service for the latest cell & gene therapies.

Our solution is a working prototype that is able to track chain of identity, custody, condition and diagnostic for autologous cell therapies. It ensures transparency for regulators, enables efficiency by reducing HIPAA compliance requirements and records are ultimately more secure. All with the ultimate aim to support improved patient outcomes.

We also believe that the blockchain will be a key enabler in decentralising the manufacturing process to ultimately take these new therapies closer to the patient.

Because of this we are developing significant knowledge and skill based on these new technologies for the digitised healthcare and medicines agenda, and specifically in the smart and connected logistics supply chain that are applicable globally, thereby making the UK the go to place for this type of expertise.

View the FarmaTrust Explainer Infographic – click here.

 
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Clinical trials and evidence / Digital health
Benefit to NHS:
The features of our solution will provide the following benefits:
  • A foundational system that is interoperable with the multitude of hardware and software systems which are used in many healthcare settings around the world, including the NHS
  • By ensuring data integrity between the various systems, scanners and data input devices without having to make substantial integration changes
  • By creating efficiencies through automating payment processes, regulatory reporting, compliance and audit
  • By utilising blockchain with AI to mine data collected in order to maximise cost savings and delivering improved services with the same budget or less
  • By providing a truly connected and smart data collection system across the multiple stakeholders to benefit the research teams, NHS, regulators and ultimately patients
  • By providing a real alternative way to do things differently to the traditional legacy cloud-based technologies that will start to struggle with the increasingly digital future of healthcare and medicines/devices
  • By leveraging the innate properties of blockchain to enable effective co-operation between competing CGT manufacturers
  • Enabling future readiness for a world that moves from the current increasingly resource hungry and inefficient supply chain model to a decentralised efficient (on) demand driven chain reality!
                                                                 
Initial Review Rating
3.80 (1 ratings)
Benefit to WM population:
Our Innovation will:
  • Develop an effective and robust CGT supply chain solution for any research team in the WM involved in CGT development, eg Midlands & Wales ATTC
  • Expose and eliminate inconsistencies and errors, thereby give therapy quality assurance to WM researchers and patients involved in trials
  • Have the potential to remove product loss completely from the high value supply chain
  • Support on outcome based value proposition for precision medicines and high value therapies based on blockchain smart contracts
  • Be interoperable with blockchain advances, incumbent cloud technology providers and the latest IoT sensors used in the WM – less money spent on tech integration and more spent on patient care
  • Leverage machine learning for data analytics which provides predictive and prescriptive insights to allow greater efficiency, cost saving and demand planning for supply logistics
  • Help make the WM and the UK a global thought leader for blockchain (enabled by Internet of Things and Artificial Intelligence) developed healthcare services!
Current and planned activity: 
We have a working solution that is:
  • Already available through our US partner. As of late 2018 Systech One are white labelling and marketing our linear small molecule supply chain solution in the US and Europe. Systech One powered by FarmaTrust!
  • A fully working blockchain based needle to needle tracking solution prototype as a result of a significant commercial partnership with a German cell & gene therapy solution provider.
  • Creating increasing interest with the Innovate UK Catapults. Namely the Digital Catapult, Cell & Gene Therapy Catapult and Centre for Process Innovation.
  • Going to be a pilot in a province of Mongolia as commissioned by their Govt – this will be our small molecule linear track and trace solution
  • Going to provide track and trace services for medicinal cannabis plants. Work that has been commissioned by Peterson One for the Thai Govt
We are also working with a senior Oncologist from Birmingham to spec our new clinical trial tracking solution.
What is the intellectual property status of your innovation?:
Core IP belongs to FarmaTrust.
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
1 year
Ease of scalability: 
3
Read more
Hide details
Raja Sharif 28/01/2019 - 11:53 Publish Login or Register to post comments
6
4
Votes
-99999
Innovation 'Elevator Pitch':
A one-day hands-on interactive training workshop. Percentage & proportion data can't be analysed statistically unless transformed because spurious, misleading results occur. You'll learn appropriate transformations, useful analysis & display methods.
Overview of Innovation:
Percentage & proportion data (known as compositional data) can't be statistically analysed reliably unless appropriately mathematically transformed, as was recognised as long ago as 1896. But no-one discovered suitable types of transformation until the 1980s. These are not at all well known, beyond a small group of mathematical statisticians, because all the publications contain difficult, advanced mathematical explanations unsuitable for the average potential user. 

This one-day hands-on, interactive training workshop will briefly introduce two of most straightforward ways of transforming this commonly occuring type of data that you can easily learn. Then you will learn briefly about some of the appropriate types of statistical analysis, meaningful ways of displaying the data and the results of their analysis. Emphasis will be on introducing how to interpret these results and the displays of those in ways you can use and explain to colleagues. 
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Education, training and future workforce / Clinical trials and evidence / Digital health
Benefit to NHS:
Gain an understanding of meaningful and reliable ways to analyse percentage and proportion data, which are so commonly found in so many areas of work in the NHS. Avoid the problems arising from spurious, inappropriate analyses of such data which are normally used which may give very misleading results.
Benefit to WM population:
Getting meaningful results of analyses of appropriately transformed percentage and proportion data will support and enable better decision making.
Current and planned activity: 
I have recently provided several 2-hour introductory seminars on statistics and on research methods to the CRN(WM). I shall be offering other hands-on, interactive training workshops through this year on clinical statistics, design analysis of clinical trials of clinical diagnostic technologies and other applied statistics topics, e.g., quality control, experiment design and analysis, statistical graphics, statistical sampling strategy design and analysis. 
What is the intellectual property status of your innovation?:
Copyright on workshop training materials
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Read more
Hide details
Dr. John Michael Thompson 26/11/2018 - 13:30 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
Liva Healthcare empowers patients to manage or reverse their chronic disease through expert behaviour change coaching. Liva is an evidence-based hybrid service leveraging human empathy and technology to achieve sustainable, positive health outcomes. 
Overview of Innovation:
Liva Healthcare has over 16 years of industry expertise, with over 140,000 users through the behaviour change intervention to date.  Liva is an innovative digital health coaching platform for scalable lifestyle and disease management.  
  
Winner of 'Health IT  Firm of th e Year' at the HealthInvestor Awards 2018 and 'Healthtech Innovators of the Year - Europe' at the Global Health & Pharma Awards 2018, Liva Healthcare is used  by  public healthcare, private insurance and pharma companies including : - NHS  England, AXA PPP Healthcare and Copenhagen Municipality.  
  
Liva  Healthcare’s platform facilitates ongoing,  personalised Health Coaching through an intuitive app, building a unique, empatheticbond between Health Coach and patient.  Its focus lies  in tackling chronic diseases such as type 2 diabetes, obesity and heart disease by  driving behaviour change.   
   
Currently being used in the UK, Denmark and Sweden, the app is multilingual across several languages. It is proven to work efficiently across all socio-economic backgrounds and is capable of engaging historically hard to reach areas and demographics. The service is based upon 9 to 18 months  of  continuous  patient  engagement to form new habits for good.  Each Health Coach  can  manage up to  500 patients per year full time without the loss of patient outcomes.  
  
Implementation time from get-go is normally within weeks and the platform is available as a white-label SaaS platform, or as a turn-key solution, dependent on client specifications.  
  
Liva  Healthcare has Headquarters in Marylebone, London and Copenhagen, Denmark. 
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
By helping to both prevent and cure chronic lifestyle diseases, Liva consequently relieves the cost pressures on healthcare systems.  Unhealthy lifestyles lead to significant cost pressures on healthcare systems. For example, in the UK it is claimed that type 2 diabetes costs the National Health Service (NHS) £8.8 billion per year, which equates to almost 9% of its annual budget and causes 20,000 early deaths per year. In addition, it is estimated that obesity costs the NHS over £5 billion per year.   
 
The platform allows Health Coaches to monitor up to 500 patients siumtaneously. This enables the NHS to save costs as the digital health tool can help patients come off medication safely. It also drives efficiency by enabling more patients to be monitored.  
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
The primary benefit that Liva Healthcare provides patients with is the opportunity tp make long-term, and SUSTAINABLE lifestyle changes to diet and exercise, with the help of a personal Health Coach, that can prevent or remove their lifestyle disease (e.g. type 2 diabetes, obesity or heart disease).  
 
Liva was designed to help prevent and reverse chronic diseases caused by unhealthy modern lifestyles, such as type 2 diabetes and heart disease, both of which are often caused and affected by weight gain.  The app is based on clinical research that has shown lifestyle interventions can lead to long-term lifestyle change and help patients reduce their risk of the disease or enter remission by losing weight.  
 
For example, Liva Healthcare monitored the progress of 136 patients using its digital healthcare app to prevent and roll back type 2 diabetes over a nine-month period. Over the period, 82% of the patients (112) lost weight, losing an average of 6.3kg, demonstrating signs of a successful lifestyle intervention.  
Current and planned activity: 
In response to this crisis, the NHS chose Liva as one of five providers to tackle type 2 diabetes using digital innovations. GPs can now refer patients at risk of type 2 diabetes in North East London, Humber, Coast and Vale to use the Liva app. Patients are given a personal Health Coach and an app to help monitor and track their health goals. The app is based on strong evidence that has shown lifestyle interventions - delivered digitally - can lead to long term lifestyle change and help patients with - or at risk of developing - type 2 diabetes reduce their risk of the disease or enter remission. Liva holds a firm belief that prevention is better than cure. Though, in many instances, its platform has been proven to facilitate both. 
What is the intellectual property status of your innovation?:
We are fully aligned to NHS IG and GDPR requirements, in addition to being a member of the NHS App Library and fully accredited and highly scored with ORCHA and QISMET. 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Read more
Hide details
Simon Pickup 01/10/2018 - 15:47 Publish 1 comment
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Giving one drop of blood for analysis by SOMAscan informs me of my current health status, and helps my doc give me the right advice to reverse or prevent further disease development, or guide their treatment recommendations that will work first time!
Overview of Innovation:
The measurement of 5,000 blood proteins (a quarter of the human protein repertoire) is now possible on a reproducible and industrial scale in clinically-accredited central lab settings. Prior analysis of hundreds of thousands of study subjects' and patient blood samples, whose basic & physiological measurements, life style and clinical histories have been collated, has been used to create a suite of health status defining algorithms that define risk of disease event occuring over 1-5 year time horizons, rates of development, and likelihood of response to alternative intervention that are available.  Whereas rudimentary 'disease risk' insights such as Framingham cardiovascular diasease (CVD) risk scores and QRISK2 are used in public health, primary care and specialist acute care settings to augment disease prevention or guide optimal treatment choices, it is now possible to expand this range of probablistic medicine insights.  Expanding the repertoire beyond CVD to include pre-diabetes conversion to full diabetes or development of complications (amputations, kidney failure, blindness) that lead to costly or catastrophic outcomes, is a starting point.  However, diseases such as non-alcoholic fatty liver disease and steatohepatitis, which leads to liver cancer & failure is another silent killer whose development can be revealed just by applying a different status-prognosis algorithm to protein measurements derived from the same blood sample.  Chronic disease management and care accounts for ~70% of healthcare costs with diabetes alone consuming 10% of the NHS' entire budget and so these are worthy of attention for  prevention, early disease interception (at a reversible stage), or optimising existing care paths that maximise available resources to deliver disease management interventions.  Our primary focus is to prolong and improve population wellbeing such that patient treatment outcomes leads to broad adoption.  However, whereas traditional diagnoses rely heavily on clinical symptoms, SomaLogic's AI-derived algorithms consider the molecular underpinnings of disease.  Clinically-defined diseases are treated in standardised ways which doesn't always work.  Identifying patients with treatment-refractory disease could help target those into research programmes including clinical trials for novel regimens or pharmacological agents.  A secondary output of routine adoption could be creation of an accelerated trial recruitment resource to attract pharma partners.
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Healthcheck, although ultimately funded by Public Health England, commissioned by City Councils and delivered through contracted CCGs/GPs, is of questionable value.  A battery of tests whose results are combined with additional clinical parameters and a consultation with a GP or practice nurse, is designed to pre-empt intervention in patients with rising risk for cardiovascular disease or identified as having 'frank' disease.  The net contribution based on opportunity savings delivered to the NHS and the cost of delivering the HealthCheck programme is close to zero.  The repertoire of diseases whose status can be tested for, could be expanded to include multiple silent diseases, as well as provision of range of physiological status-related insights that could complement the patient review process.  For example, patients at risk of developing frank diabetes could be managed more objectively and successfully.  A reduction by 1% of patients converting to full diabetes could equate to £100 million/year by their avoidance of costly complications such as stroke, amputations, kidney failure and blindness.  Avoidance of liver failure associated with liver fibrosis, could contribute further significant opportunity savings: Coupling life style (e.g. dietary education or excercise on prescription) or emerging pharmacological interventions with conveniently measured disease status insights will be required.  However, rather than creating increased burden on NHS resources, provision of clinically validated insights but could also create opportunities for third party organisations beyond the NHS in offering relevant health-maintaining or disease-reversing solutions.
Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:
In a county in which 29% of the population is clinically obese there is a higher risk compared to the majority of the UK population, for diabetes and also fatty liver disease-related complications.  Treatment costs for the latter alone costs the NHS (England) around £1billion/year.  Providing disease risk insights to citizens and their health practictioners, particuarly if the information is objective and made actionable, could be used to support increased health literacy, increase patient activation (motivation), and support the best choice and resource-optimal delivery of advice and clinical interventions.  Ultimately, compliance with such advice and insights will improve the healh of the local population, reduce the burden of dependancy on long-term chronic disease care, and perhaps even result in development of a health-focused preventive health solution provider market.
Current and planned activity: 
SomaLogic has submitted plans for implementation of diabetes risk and complication development predicting algorithms in the routine primary care setting in Leeds (one CCG and 3 GPs). The objective is to use the more objective patient profiling (identified through hypertention clinics) to promote deeper patient enagement measured through increased patient uptake of commissioned nutritional education programmes and/or gym by prescription.  Logistics around blood collection, processing, analysis and data delivery and presentation will be evaluated and optimised, after whcih there is scope to expand this initiative to a wider geographical region.  However, there is scope to evaluate the utility of additional disease status (risk), and prognostication algorithms within the different clinical settings and associated clinical workflows, in neighbouring geographies.
What is the intellectual property status of your innovation?:
SOMAscan is a patented proprietary protein measurement technology.  Algorithms developed using artifical intelligence to mine for associations between patient characteristics, lifestyle histories, clinical interventions and decades of clinical follow-up/outcome data (2 million years) that correlate with patterns for 5,000 protein measurements (mined from 2 billion protein data points), provides a highly defensible starting position.
Return on Investment (£ Value): 
Very low
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
2
Read more
Hide details
Anthony John Bartlett 11/07/2018 - 16:11 Publish 3 comments
6
1
Votes
-99999
Innovation 'Elevator Pitch':
Our web based visualisations of NHS datasets is disrupting the analytics market. It allows systems to understand cause and effect within their health economies and test hypothesis in real time by interacting with the data through drop down menus
Overview of Innovation:
Our vision is to give every NHS system leader in England a clear picture of the end to end journey for the populations they serve. At the same time we aim to save the NHS £millions by disrupting the market for low level analytics!
The challenge currently faced by all healthcare leaders is a lack of insight and meaningful, consistently-reported analysis regarding the position and performance of the healthcare system. This lack of insight hampers the efficacy of the strategic and operational planning process and the scope and effectiveness of monitoring and oversight.
This challenge sits in the context of masses of existing publicly available healthcare data. Data that’s time consuming for providers to prepare but underutilised due to its format, shape and local capacity and capability.
Our vision is to make VUIT.ONLINE, our information and insight portal, available across the entire NHS in England. The tools we’ve developed allow users to interrogate data across an provider, CCG, ST or ICS quickly and efficiently in a way which informs decision making and allows the impact of interventions to be validated using existing national datasets.
VUIT.ONLINE re-configures, combines and visualises NHS and other national datasets in a way that allows them to be used to understand system and provider performance and demand in context.
Our front-end combines different datasets to create insights not available from any one alone, for example combining DTOC data with hospital bed-base to understand the effective scale of the DTOC issue, or comparing RTT data with consultant workforce to contextualise waiting list trends.
By doing this we can support system leaders to gain a deep understanding of cause and effect related to key strategic issues within their ICSs and model the impact of decisions they may wish to make to address those issues.
All this is achieved with data which is consistent across all providers, layered from multiple data sources and, most importantly is instantly available, at the national, regional and place based level for comparison and analysis through an online portal.
The impact of VUIT.ONLINE is not just the creation and availability of new insights from data, but the speed at which it can be manipulated to test hypotheses.The financial viability of VUIT.ONLINE comes from its ability to deliver this with an absolute lack of in-house or procured analytical or BI resource in the form of consulting and CSU costs which currently run into many millions.
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Clinical trials and evidence / Innovation and adoption / Person centred care
Benefit to NHS:
VUIT.ONLINE re-configures, combines and visualises NHS and other national datasets in a way that allows them to be used to understand system and provider performance and demand in context.
We do this in a pre-packaged but evolving, continuously-updated front-end combining different datasets to create insights not available from any one alone, for example combining DTOC data with hospital bed-base to understand the effective scale of the DTOC issue, or comparing RTT data with consultant workforce to contextualise waiting list trends.
By doing this we can support system leaders to gain a deep understanding of cause and effect related to key strategic issues within their ICSs and model the impact of decisions they may wish to make to address those issues.
All this is achieved with data which is consistent across all providers, layered from multiple data sources and, most importantly is instantly available, at the national, regional and place based level for comparison and analysis through a scalable online portal.
The impact of VUIT.ONLINE is not just the creation and availability of new insights from data, but the speed at which it can be manipulated to test hypotheses at system level from the system’s own, current data within existing national datasets.
The financial viability of VUIT.ONLINE comes from its ability to deliver this with an absolute lack of in-house or procured analytical or BI resource. A fundamental success factor for the implementation of this innovation is a reduction in the cost of low-level analytical support to the NHS in the form of consulting and CSU costs which currently run into many millions.
Initial Review Rating
3.00 (2 ratings)
Benefit to WM population:
By giving system leaders the tools they require to effectively build end to end, whole system pathways and commission them outcomes will improve for the people of the West Midlands. However the way in which our innovation VUIT.Online is configured this benefit is freely available to all health economies in England
Current and planned activity: 
We are currently mid way theought the second wave of Test Bed applications where we are both an innovator and a defined test bed partner with a West Midlands CCG
What is the intellectual property status of your innovation?:
VUIT. Online and it's intellectual property is owned by its co-founders. It is built on licenced propriatry software and uses national data sets which exist in the public domain
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:
VUIT. Online uses national data sets, propriatery analytcal software and globally recognised web developer frameworks (wordpress). As such it is scaleable across the entire NHS in England immediately
Measures:
Measurable outcomes:
-reduction in spend on low level analytics in the NHS in england
-reduction in patient pathway costs as health economies understand whole system costs more effectively and plan ICS's on this basis
-Improved ability to scale innovation in healthcare by giving innovators access to data which will support, clarify and stratify the way in which they develop and take their products to market
Adoption target:
We aim to make the resource available to all NHS managers in England through sharing examples of best practice around the use of VUIT.Online
Read more
Hide details
Adam Townsend 25/04/2018 - 15:31 Detailed Submission Login or Register to post comments
6
1
Votes
-99999
Innovation 'Elevator Pitch':
RespiraSense demonstrated a potential for 6-12 hours earlier detection of patient deterioration when compared to the standard of care. Putting that into context, for every 30-minute delay in treating Sepsis, increases the risk of mortality by 7%.
Overview of Innovation:
RespiraSense is the world's only continuous respiratory rate monitor. Respiratory rate is the earliest and single most sensitive indicator of patient deterioration, more so than heart rate if systolic blood pressure. In fact, 26 breaths per minute are considered the earliest point of divergence between Spo2 and respiratory rate. Giving rise to 12+hours of false security is accurate RR is not measured. 

The standard of care remains the manual counting of breaths per minute, which has been shown to be biased and prone to error. With evidence showing no change in the quality of measurements for over 170 years (1846SirHutchenson) (2017Badawy). 

RespiraSense gives medical teams the advantage of being able to intervene early, thus reducing time to intervention and improving outcomes. Outcomes such as Average Lenght of Stay, Average Unit Cost of Care, and Patient Safety targets can be achieved. 

RespiraSense is a simple, wireless, and discrete wearable monitor, placed on at admission and worn/measuring continuously for upto 7 days. Each patient recieves a new sensor and a reusable electronic device or Lobe. See how the system works @ 
https://www.youtube.com/watch?v=u6KB1hBPQbM​ 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Each year, there are approximately 500,000 admissions of Sepsis and Pneumonia with an average unit cost of £4,600 per admission. These two conditions are increasing in incidence and oftentimes lead to an escalation of care due to the risk of undetected deterioration. It is shown that a 5% reduction in the escalation of care of these two pathways alone, through the use of continuous Respiratory Rate monitoring triggering decreased time to interventions (Fluids, Oxygen, Antibiotics, Steroids), can reduce the average unit cost by £300 and the average length of stay by 0.5 days. This translates into a total Net cash saving of £115m and 250K bed days. Popular opinion suggests that as high as 20% reduction is achievable - Evidence pending. 

Each event prevented, having an average cost of £25,000, will pay for a whole year's supply of sensors for one year. 
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
West Midlands Trusts are driving the awareness of Sepsis through their ambulance services, patient awareness campaigns, and in-hospital initiatives. With 44,000 lives lost each year attributed to Sepsis, it is important to Prevent, Diagnosis Early, and Effectively Treat the condition. RespiraSense focused on the area of Diagnosis Early. Research suggests that NEWS2 is a more sensitive indicator of deterioration due to Sepsis than QSOFA. Both of which have Respiratory Rate as a key parameter to measure. There is clearly value in monitoring this essential vital sign accurately, and clear additional benefit to having it monitored continuously. RespiraSense achieves both with low impact of False alarm due to its innovative design, boasting advanced motion-tolerance. 
Current and planned activity: 
PMD Solutions is working with Nursing Times to launch an educational campaign on the clinical science and importance of respiratory rate monitoring in acute care clinical practice. 

In addition, PMD Solutions is looking for Respiratory and Emergency teams to partner with and create a culture of Peer Leadership in the development of best practice for respiratory rate monitoring. 
What is the intellectual property status of your innovation?:
RespiraSense is positioned to be the new industry standard in respiratory rate monitoring. It is patented in Europe, United States, China, Hong Kong, and Japan. 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
2
Read more
Hide details
Myles Murray 02/03/2018 - 20:46 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
Reduce the time it takes for clinicians to find clinical trial options for patients and increase trial enrollment rates.
Overview of Innovation:
It requires significant time to evaluate open clinical trials, analyse inclusion/exclusion criteria and determine a patient’s eligibility for trials based on all the relevant information in the medical record.
Watson for Clinical Trial Matching eliminates the need to manually compare enrollment criteria with patient medical data, making it possible to efficiently identify the potential trial options. It generates a ranked list of relevant trials for each patient

This increases patient access to clinical research, improves trial enrollment, and reduces trial delays.
See details and a video at: https://www.ibm.com/watson/health/oncology-and-genomics/clinical-trial-matching/
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Clinical trials and evidence / Innovation and adoption
Benefit to NHS:
Saves time in evaluating Clinical Trials available to your patients and their eligibility. Improves Trial enrollment rates - making new treatments available quicker for patients.
Initial Review Rating
3.00 (2 ratings)
Benefit to WM population:
Potential to be the first region in England to use this technology and make trials and new treatments available quicker for patients.
Current and planned activity: 
Currently deployed in healthcare outside UK. We are looking for organisations who will prove the solution works and delivers benefits in the UK.
What is the intellectual property status of your innovation?:
IP is IBMs
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
David Clarkson 26/02/2018 - 14:46 Publish 1 comment
3
1
Votes
-99999
Innovation 'Elevator Pitch':
Feedback Centre enables organisations to collect feedback from any stakeholder. This information is presented via a visual dashboard called Informatics, allowing health organisations to spot trends & issues and act on them or plan improvements.
Overview of Innovation:
Feedback Centre has been developed in collaboration with and for the NHS and Health & Social Care organisations.

Feedback Centre brings together public feedback, survey results and complaints, all of which can be shared directly with stakeholders/service providers. This allows data from multiple sources to be joined-up, stored in one place and shared organisation-wide. 

Feedback can be collected online, including by tablet, mobile, Facebook and via widget, as well as via SMS and kiosk. This offers a great choice for patient engagement and allows patient experience teams to gain information from a broad cross-section of society, as different social, economic and clinical groups often communicate via very different means. The system also allows offline and archived feedback collected from other sources to be imported into Feedback Centre.
                                                                                                           
Feedback Centre also includes a screen-reading and translation feature with the aim of preventing the exclusion of those with visual impairments or poor literacy skills from engaging with providers.
 
Health & Service providers are able to respond publically to feedback, shortening response times to public concerns and reducing the volume of incidents that escalate to formal complaints.
 
Our business intelligence dashboard, Informatics, presents the fastest way possible for Health organisations/Trusts to access data, understand trends and create reports. It will also provide clients with the ability to utilise their own taxonomy, categorising the data in any format required. This allows for benchmarking of providers, services and departments, as well as identifying areas for potential improvement.

Utilising sentiment analysis, Feedback Centre will determine the emotional tone behind a series of words. This can be used to gain an understanding of the attitudes, opinions and emotions expressed within a review or complaint. Thus they can be weighted for seriousness and therefore flag providers to take note and take instant action
 
To ensure confidentiality the system is hosted by EKKO securely to NHS Trust information governance standards with monthly updates provided to the platform. 
 
To see Feedback Centre in action, take a look at the following video featuring Healthwatch and NHS England: http://www.EKKOmedia.com/healthwatch-video/
 
Benefits:
  • Branded system for any organisation
  • All information available in one place
  • Secure, ISO27001 Hosted Surveys and GDPR ready
  • Less risk, all information is shared directly with client only
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
A single database for ALL experience data: The key benefit to the NHS is the storage of all user & staff experience data into a single database, which can be, used organisation-wide by an unlimited number of users with different levels of access. Hence this aggregation of data provides:

A facility removes the risk of inefficiencies due to having multiple, unconnected silos of disparate information, training is provided every step of the way by EKKO.
  • Peace of mind for GDPR compliance and ISO27001 hosting, utilising world leading hosting architecture Amazon Web Services.
  • An ability to create a snapshot or larger historic overviews of analysed data on single aspects or wider views of experiential data and trust feedback    
  • Services and providers to be benchmarked, allowing the identification of top performers or highlighting underperforming providers or departments. Alternatively it can show issues where quality or care does not match KPI’s, indicating a need for investigation or a comparison to be made. 
     
  • Creation of specific taxonomies; Trusts can categorise their data to ensure that the words and meanings meet that of their patients within in different clinical, social and ethical groups, so as to remove barriers whilst ensuring data integrity and meaning is maintained when analysed and reported on.
     
  • Through the multi-channel approach it allows Inclusivity and increased response rates while maintain data cohesion. Feedback Centre can be used to engage with a broader cross-section of society, resulting in higher response rates for surveys. e.g. young people and those within the working population are often unable to attend Patient Participation Group (PPG) meetings, meaning they are often under or not represented in survey results. Allowing those groups to complete a survey via a smartphone or Facebook application which increases the likelihood of gaining a more representative sample within the Feedback Centre database.
     
  • Cost savings on external surveys suppliers - The system can be used to administer the Friends and Family Test, as well as any other mandatory or ad-hoc NHS surveys, including staff surveys. Using the system for surveys removes the need for external partners to conduct surveys, hence a significant saving. (The system has no limit on users or the creation of custom surveys, thus no additional costs per survey). Whilst also ensuring all survey data is held by the Trust and in one place for future reference and analysis.

Initial Review Rating
4.80 (2 ratings)
Benefit to WM population:
How do the public see their responses or outcomes/results of feedback they give?



Give YOUR Patients & the Public a voice for feedback and complaints
We provide the WM population with a place to share feedback safely about services that they use. All health and care providers can feature on the system. Feedback is displayed publicly after moderation, allowing anyone to compare and benchmark providers based on real experiences.
 
The system is multi-channel, inclusive and easy to use
A significant proportion of the NHS’s engagement is done via Patient Participation Groups (PPGs). PPGs are not always representative re: age, race & gender, as well as numerous other demographic factors. This is due to people being unable to attend PPG meetings due to being at work, school or condition they are being treated for. By offering a multi-channel solution, members of the public are able to leave feedback online, increasing the likelihood of gaining direct feedback and insights from those groups. A text-reader service can be added to the site to enable those with visual impairments and speakers of other languages to give feedback.
 
Our technology can be used to broaden ways users engage in feedback. Thus we wish to work with health providers to explore & develop such processes & systems.
 
Provider responses
Service providers are able to respond to reviews publically or privately, addressing concerns before they escalate into serious issues or formal complaints. This demonstrates to the public that they are being listened to, inspiring confidence in services & can be used to intervene in more serious alerts & complaints.

Branded, secure portal
The system is branded to health clients’ guidelines to ensure uses have confidence with whom they are engaging with and responding too. Security and hosting is to NHS Trust IG standards with Amazon Web Services. All data is hosted in the UK and load-balanced, ensuring availability of systems at all times.
 
Using a secure, online portal offers a greater level of security than collecting data offline/paper, as well as providing significant cost savings. Currently, most patient experience data is collected and stored offline in a multiple, which has implications in terms of the GDPR regulations that come into effect in May 2018.
 
Monitoring & reporting on changes
Centralisation of cohesive data provides the ability to compare and contrast between service, timeframes and as a way of gauging and monitoring any changes that are made.
 
Current and planned activity: 
Current
We work with NHS trusts, CCGs, Healthwatch network & local. System is showcased at UK events with major update due -Feedback Centre 2.0. Long term aims are to roll-out across NHS, Care & Housing sectors

Regional Scalability
Explore West Mids roll out as it has not yet been scaled across an entire NHS region previously. NHS E & SWAHSN funded regional roll-out across 7 Healthwatch network organisations
 
Individual CCG, Trusts, STP, Healthwatch & GP federations uses are possible. Regional or large scale adoption could provide individual as well as wider insights to services & their performance & satisfaction levels.
 
Wish to hear from
Organisations wanting Feedback Centre demo: - GP, CCG, Trust or other health/social care provider
 
Evaluation & Validation of system benefits, monitoring delivery, ensuring + patient experience
 
Product Development – expand ways patients can engage & provide feedback
 
What is the intellectual property status of your innovation?:
Feedback Centre is copyright protected, having been created by EKKO. Data held within the system is the IP of the client, with EKKO performing the role of data processor.

Regulatory Approvals:
EKKO hold the following approvals: 

Cyber Essentials: EKKO have completed Cyber Essentials, a Government-backed, industry-supported scheme to help organisations protect themselves against the most common threats found on the internet.

GDPR Foundation Certification – EKKO have completed this certification with the aim of helping our clients prepare for the new regulation requirements.

Data Protection Public Register: ZA310893
 
IG Toolkit – EKKO are currently working towards the IG Toolkit and aim to have this completed by April 2018. 
 
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
2
Read more
Hide details
Ian Hughes 15/02/2018 - 18:28 Publish 1 comment
5.5
2
Votes
-99999
Innovation 'Elevator Pitch':
Natural insulation to improve internal building air quality within both new build and refurbishment health properties.
Overview of Innovation:
Grenian are a specialist company offering natural insulation for both new buildings and refurbishment projects. Natural insulation is sourced from naturally occuring fibres such as sheep wool, hemp, wood and cellulose fibres. All of our insulation products are manufactured with harmless binders such as recycled polyester binders.
​In adiditon research has been published showing that natural insulation can help to improve building internal air quality such as reducing formaldehyde levels. We have supplied insulation on a number of health projects such as Maggies centre, Oldham. The centres offer support for patients suffering from cancer. In Germany research has been carried out showing that schools internal air environment improved by utilising sheep wool insulation in the internal building fabric.
​These examples confirm that natural insulation is a viable alternative to man made insualnts.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wellness and prevention of illness / Clinical trials and evidence
Benefit to NHS:
Studies have shown that natural insulation can help to improve both existing and new building internal air quality. As a result patients potenitally will experience reduced respiratory ailments and conditions. Theoretically this would help to reduce cost burden of treatments for the NHS.
Initial Review Rating
2.20 (3 ratings)
Benefit to WM population:
Our innovation will potentially help to reduce patients respiratory conditions resulting in reduced illness and sickness. This would potentially help to increase productivity and reduce sick days.
Current and planned activity: 
We are not currently involved in direct communications with the NHS or other health authorities. However we have worked with national architects on health and well being projects where specification of suitable materials for the building fabric is a key factor within the design process.
What is the intellectual property status of your innovation?:
We supply materials from a variety of manufacturers who hold intellectual property on the various insulation products.
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Rejection Reason:
Unable to contact Innovator to clarify aspects of submission.
Read more
Hide details
Matthew Nalborczyk 31/05/2017 - 14:26 Rejected Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
Coronary Artery Disease (CAD) is the leading cause of death world-wide. HeartFlow’s non-invasive technology, FFRct, has been found to accurately diagnose patients with suspected CAD, avoid unnecessary invasive procedures, and reduce healthcare costs
Overview of Innovation:
The diagnosis and care of patients with suspected coronary artery disease is significantly improved by the use of HeartFlow's FFRct analysis. Our process starts with data from a standard Coronary Computed Tomography Angiography (CCTA). High-quality (64 slice or greater) CT scanner images are sent to HeartFlow.

HeartFlow then creates a personalized, 3D model of each patient’s arteries. Where computational fluid dynamics are used to evaluate blood flow and assess the impact of blockages in the arteries. With this actionable information, clinicians can determine the right course of action for each patient.

While FFRct is still in an early  stage of adoption, there are now over 150 publications on the technology. Clinical trials have validated both the diagnostic accuracy and clinical utility. Most recently NICE issued guidance on HeartFlow FFRct, stating "The technology is non-invasive and safe, and has a high level for diagnostic accuracy... may avoid the need for invasive coronary angiography... Based on current evidence using HeartFlow can lead to cost savings of £214 per patient."

CT data is securely (Anonymised CCTA data) and seamlessly sent via our “HeartFlow Connect” once installation is approved by the hospital trust. HeartFlow ensures that the scans and FFRct results and analysis models are acceptable to a sites radiologists / radiographers.
 
Whilst this is an emerging diagnostic its well positioned to become an integral part of standard patient care for those who are at risk of CAD. As this is a new technique HeartFlow provides training to radiologists, radiographers, cardiologists and support staff. We work closely with each site to provide support and training to help evaluate the technology and as they begin to incorporate FFRct into their clinical practice. [A high level overview of HeartFlow’s training support can be found in the Adoption guide published by NICE. (see attached)]
 
HeartFlow FFRct users are invited to educational seminars and we are working on establishing a UK users group to help sharing best practice around FFRct’s use.
 
HeartFlow has received CE mark approval for use in UK/Europe.  CCTA image specifications for HeartFlow FFRct analysis; HeartFlow’s CCTA quality requirements are consistent with those of the Royal College of Radiology (RCR), British Society of Cardiovascular Imaging and the Society of Cardiovascular Computed Tomography (SCCT) performance of CCTA guidance document.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption
Benefit to NHS:
The use of HeartFlow FFRct can improve patient care, efficiency, and lower medical costs:

Patient Care
  • HeartFlow FFRct provides a physician with both functional and anatomical data, improving diagnostic accuracy, thus reducing invasive procedures and associated complications
  • Improved diagnostic accuracy improves patient care and quality of life
  • Studies suggest that incorporating FFRct lowers patient radiation levels due to decreased angiography
Efficiency
  • Studies indicate that the application of FFRct may result in a reduction of unnecessary angiographies, improved cath lab efficiency, and reduced waiting lists
  • By providing both functional and anatomic data, physicians may be able to reduce the need for and waiting times associated with other diagnostic imaging tests
Cost of Care
  • As demonstrated in the NICE guidance, the use of HeartFlow FFRct can potentially reduce the cost of care. NICE estimates an average savings of £214 per patient. This saving is based on not conducting inappropriate invasive diagnostics.
  • A Japanese study has indicated that the use of the CCTA-FFRct strategy to select patients for Percutaneous Coronary Intervention (PCI) would result in 32 % lower costs and 19 % fewer cardiac events in 1 year compared to the most commonly used CAG-visual strategies. 
 
“The HeartFlow FFRct Analysis provides a definitive understanding of both anatomical and functional findings, without any additional testing or risk for patients. Application of the HeartFlow FFRct Analysis is likely to transform the quality of care we can provide for patients, ensuring the most accurate diagnosis and the best treatment plan, as well reducing the need for invasive coronary angiography – a procedure not without its risks.”
  -  Dr. Joseph Mills, Liverpoool Heart and Chest Hospital
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
As stated in the NICE guidance, the adoption of HeartFlow FFRct in the West Midlands region could improve patient care and outcomes while generating significant savings for the region.
 
We are looking for additional adoption sites and would be interested in hearing from West Midlands Trusts that would like to take the lead in establishing our UK user group.  
Current and planned activity: 
HeartFlow is in early conversations with NHS Trusts and commissioners. A handful of early adopting NHS medical centres have begun to provide HeartFlow FFRct for their patients. HeartFlow is engaging with interested physicians at centres with high quality CT capabilities.

UK Sites where Heartflow FFRct is being used:
  • St. Bartholomew’s Hospital (London)
  • Liverpool Heart and Chest
  • Russell Hall Hospital (Dudley, West Midlands)
  • Freeman Hospital (Newcastle)
HeartFlow is in discussion with other UK site about adoption of FFRct.

Planned / required activity
  • We are looking for additional adoption sites and would be interested in hearing from Trusts that would like to take the lead in establishing our UK user group 
  • Whilst we have undertaken worldwide studies we are always interested in ongoing evaluation / validation and collaborative developments technically and with clinical pathway integration.
  • In the future we plan on conducting clinical trials based & focused on specifically the UK population.
What is the intellectual property status of your innovation?:
HeartFlow has established significant intellectual property and has been issued several patents.
HeartFlow received CE IIA mark approval for use in UK/Europe in July 2011. The technology is also ISO 13485 certified.  

Return on Investment
Savings have been demonstrated in clinical trials (PLATFORM), third party health economic modelling (NICE guidance, Int’l Journal of Cariology 183 (2015) 173-7), and real world experience at early adopting centres.
 
NICE recommendations for Heartflow FFRct (February 2017) state:  “Using HeartFlow FFRct may lead to cost savings of £214 per patient. By adopting this technology the NHS in England may save a minimum of £9.1 million (annually) by 2022 by avoiding invasive investigation and treatment.  
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
2
Regional Scalability:
Liverpool Heart and Chest has performed more HeartFlow analyses than any other site. They have demonstrated clinical and economic benefits to incorporating HeartFlow FFRct into their practice. The uptake is due in part to to the strong support from their regional CCG.
Measures:
HeartFlow is seeking to achieve the following outcomes:
 - Improved patient care: Reduction in unnecessary invasive angiographies and eventually a reduction in waiting times for those patients that need angiographies
 - Reduction in Healthcare Costs: NICE estimates cost savings of 214 GBP per patient. We are working with existing sites to demonstrate real world outcomes.
 - Quality of Life: HeartFlow's clinical utility trial, PLATFORM, demonstrated an improvement in quality of life when FFRct was incorporated into patient care pathways. It is likely that this is in part due to the avoidance of unnecessary interventions. To date we have not seen any adverse events from avoiding invasive procedures.   
Adoption target:
NICE estimates cost savings of 9.1M GBP annually within five years. To reach this objective approximately 35,000 patients would need to have access to a HeartFlow FFRct analysis. 
Read more
Hide details
Ben Forrest 12/05/2017 - 18:12 Detailed Submission 3 comments
5.7
3
Votes
-99999
Innovation 'Elevator Pitch':
Airglove is a patient warming system that gently heats the arm, raising fragile or hidden veins, making them easier and less painful to access.
 
“Up to 35% of patients require heated cannulisation due to fragile or hidden veins”
 
Overview of Innovation:
Airglove is a unique warming system developed to enable access to the veins in a patients arm for the delivery of intravenous drugs. It gently heats the patients arm up as it forces warm air through a single use double walled polythene glove.


www.greencrossmedico.com/products/airglove

Patient Solution
Airglove warming system works in just 3 minutes gently heating the patients arm to the selected temperature. Its so easy to use the nurse/practitioner simply selects the chosen temperature setting according to the patients skin type, places the patents arm in the double walled polythene glove and selects start. The patient will feel the warm air fill the glove up and vent away through a single slit perforation and after 3 minutes the machine will automatically stop with an alert sound.

Patient Clinical Considerations
With extended courses of treatment such as chemotherapy repeated cannulation is often required. Airglove can benefit fragile or hidden veins by warming the local area which gently raises the veins allowing for the insertion of the cannula. This reduces the time taken, costs and the number of attempts required which is more comfortable for both the patient and nurse/practitioner.

Patient Comfort
In addition to the benefits of easier cannulisation Airglove can help to make the patient more comfortable and relaxed with its gentle warming system with the confidence that the nurse practitioner will be able to access their veins.

Temperature Settings
The temperature can be selected to suit each skin type sensitive 31.5C, normal 35.5C or slightly heavier 38.5C with the Airglove automatically re-setting itself to normal skin type (setting 2: 35.5C) after each use. After 3 minutes the Airglove unit automatically switches off with an alert sound.

Patient Safety
No more improvisation with warm water, heat packs or even heated towels to try and gain access to patients veins which can be a Health & Safety issue.

Approved Medical Device
Airglove has taken 5 years of development, research, testing and trials by Green Cross Medico in conjunction with NHS Innovations South East and The Maidstone and Tunbridge Wells NHS Trust hospital. It was developed as there was a clearly defined and acknowledged need by medical professionals at The Maidstone and Tunbridge Wells NHS Trust hospital oncology department. Further trials will be starting shortly with Beatson West of Scotland Cancer Centre, Glasgow.
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Patient and medicines safety / Person centred care
Benefit to NHS:
Airglove was initially developed for chemotherapy patients who have hidden or fragile veins and especially in patients who are in their 5th or 6th cycle of therapy.

The use of Airglove affords easier cannulation with fewer attempts being required (sometimes up to 6 attempts by 3 different staff can be attempted to access a difficult vein). This improved ease of access not only makes the patient’s experience far less traumatic, but ensures a better clinical outcome and saving valuable nursing/practitioner time and consumables.

Data regarding patient experience and resource savings. Patient evaluation trials at Maidstone and Tunbridge Wells Hospital NHS Trust showed 87.5% success in cannulation on first attempt with the most difficult to cannulate patients. With cannulation success, the potential cost savings on consumables are up to £50k per oncology unit, plus the nursing/practitioner’s time. Airglove is now available and is in use or on trial in over 10 hospital trusts with more waiting for demonstrations.

Improved hygiene and reduced risk of cross infection will result from the use of Airglove vs currently used methods of locally heating the arm e.g. hot towels or buckets of warm water. Only Airglove’s single use only, double walled polythene sleeve comes into direct contact with the patient’s skin. Heated air is circulated between the double wall of the sleeve and is not directly blown across the skin and so the risk of cross contamination is reduced.

Airglove can also be used for other interventions where venous access proves difficult due to fragile or difficult to find veins e.g. routine phlebotomy.

Airglove has been developed in partnership with NHS Innovations South East and The Maidstone and Tunbridge Wells NHS Trust Hospital (MTW). It has undergone testing by the Electronics and Medical Engineering (EME) trials for temperature control and stability, and on a cohort of healthy volunteers. The Maidstone & Tunbridge Wells NHS Trust has completed the patient evaluation trials with the oncology department. They achieved 87.5% 1st time success with their hardest to cannulate patients (MTW report available).






 
Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:
The West Midlands patients and healthcare system would equally share the benefits described above for the NHS in general.

There are 13 NHS Trusts within the West Midlands having oncology departments.
 
Current and planned activity: 
Airglove is now available in the UK.

If you would like to trial Airglove for 4 weeks contact Sheena Jack 07944 519796 or email: sheena.jack@greencrossmedico.com

Airglove has been developed in partnership with NHS Innovations South East and The Maidstone and Tunbridge Wells NHS Trust Hospital (MTW). It has undergone testing by the Electronics and Medical Engineering (EME) trials for temperature control and stability, and on a cohort of healthy volunteers. The Maidstone & Tunbridge Wells NHS Trust has completed the patient evaluation trials with the oncology department. They achieved 87.5% 1st time success with their hardest to cannulate patients (MTW report available).




We are also working on a further evaluation with the Beatson West of Scotland Cancer Centre, Glasgow, along with NICE Medical Technologies Evaluation Programme.


 
What is the intellectual property status of your innovation?:
Airglove is a registered Trademark.

Airglove is Patented Internationally.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
Simple
Regional Scalability:
We have not implemented in scale in any other region yet, as the product will not be available commercially until June 2018. From this point on it will be available to purchase across the West Midlands region directly from Green Cross Medico until available through NHS supply Chain.
Measures:
The success of the innovation will be measured by the uptake of Airglove throughout all 160+ oncology units throughout the UK.

This will also be determined by the cost savings to the NHS, along with patient comfort and safety, which will be assessed from the success of the patient evaluation and clinical trials.

Adoption target:
If Airglove is adopted by the 13 NHS Trusts in the WM region into their respective 14 oncology units, supplying 3 Airglove units per oncology unit, this represents 42 Airglove units using 127,400 gloves per annum.

This could generate potential savings of £369,460 per annum to the Regional NHS.

Our trials and experience to date has demonstrated that the use of the Airglove system improves the efficiency of the nurse/practitioner, coupled to the direct consumable cost savings mentioned previously....in addition to the patient comfort benefits.

We can see from the Maidstone & Tunbridge Wells service evaluation how much of a difference it makes to the patients comfort and safety when they can be cannulated successfully on the first attempt, and to take this to the next level where all patients not just oncology can get the benefit as there are a lot of 'old and cold' as we say that are hard to cannulate and are dehydrated too.
Adoption target:
If Airglove is adopted by the 13 NHS Trusts in the WM region into their respective 14 oncology units, supplying 3 Airglove units per oncology unit, this represents 42 Airglove units using 127,400 gloves per annum. 

This could generate potential savings of £369,460 per annum to the Regional NHS.
Read more
Hide details
Sheena Jack 10/04/2017 - 15:29 Detailed Submission 1 comment
5
1
Votes
-99999
Innovation 'Elevator Pitch':
doDOC streamlines collaboration by bringing people and processes together into a single platform, with end-to-end auditability, saving up to 70% in documentation time.
Overview of Innovation:
Life Science and Academic organizations operate in an extremely document-intensive, highly regulated environment. doDOC support this critical process of producing collaborative, compliant, quality documents within tight deadlines.
Whether working with a few individuals or large geographically diverse teams, doDOC makes the co-authoring, review and approval process less painful and more efficient by ensuring neither document quality nor deadlines are compromised in a integrated platform solution.
 
Documentation processes are typically managed in silos by multiple software in each working group of individuals leading to errors, duplicated information and delays, wasting billions of working hours every year.
 
doDOC proposal is simple: a single collaborative platform for the creation of documents with granular control over information processes and a system capable of integrating information from multiple sources avoiding duplication and manual tasks, generating a comprehensive audit trail with measurable effectiveness.


 
How doDOC does that?
1 – Streamlining collaboration and avoiding typical project miscommunication problems;
2 – Automating workflows, ensuring that the right people is doing the right thing in the right moment;
3 – Changing the writing process from a step by step reality to a concurrent and symbiotic experience;
4 – Bringing automation to technical tasks related with document production that until now undermine productivity;
5 – And since doDOC tracks every single event over the entire project, doDOC provides unique insights to allow managers and team members to track progress and access performance in real-time.
 
This change in the technology behind the creation of information allows doDOC users to decrease immensely the total time for the execution of their document-based projects.
 
doDOC Features:
Absolute Security: Full confidentiality, integrity, availability and auditability;
Real-time Collaboration: Collaborate in real-time across departments, regions and organizations.
Automatic Formatting: Full focus on content and automated publishing;
Full Control: Notifications, roles and accesses controlled automatically;
Information Integration: Centralize all records and information in one place;
Custom Workflows: Drive processes automatically and improve efficiency;
Simple Project Management: Optimize virtual teams and operations;
100% Traceability: Provide real-time insight with activity dashboards.

More about doDOC Platform: doDOC Product
More about doDOC: Website
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Education, training and future workforce / Wealth creation / Clinical trials and evidence / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
doDOC is a proven cost effective solution for the document co-authoring, review and approval process, providing an excellent return on investment (20X ROI) with both tangible and intangible benefits.
 
Key benefits to NHS by the use of doDOC is the streamlining of cooperation among healthcare professionals with impact on the following areas: patients, processes and knowledge.
 
Improved Patient Care: The complexity of managing patients’ health records requires a cooperative effort that encompasses all of the healthcare professionals involved in their care, each in his/her area of expertise, in order to achieve the best outcomes. doDOC streamlines report generation, focus on the content and decrease the time spent in administrative tasks.
 
Better Process Efficiency: Another variable mentioned when analyzing the usefulness of working together was improving the process. By employing doDOC, the organization is automating the application of standard operational procedures and ensuring compliance with best practices. This improvement in the processes leads to greater efficiency and to an increase in the quality of the healthcare given to the patients.
 
Promoting Knowledge: The importance of collaborative work was also noted for facilitating knowledge among professionals, optimizing time and resources. doDOC allows sharing information in a more effective manner. By controlling information across the network, professionals provide knowledge that is securely shared, with improved health being the result.
Initial Review Rating
3.80 (2 ratings)
Benefit to WM population:
doDOC will promote greater collaboration between the West Midlands Health Organizations: Universities / Hospitals / Companies have with doDOC a single collaborative and secure platform to create value and generate positive impact for the local population.
Current and planned activity: 
doDOC currently works with Top10 Pharmaceutical Companies and world-leading research organizations.
doDOC aims to streamline collaboration across life science and healthcare institutions by simplifying the collaborative effort within document-based projects.
What is the intellectual property status of your innovation?:
Registered Trademark
Trade Secret
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Carlos Boto 17/03/2017 - 18:33 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
SEEING WHAT OTHERS SEE, AND WHAT THEY EXPERIENCE IN THE PROCESS
Eye Control, Eye Perception, Eye Emotion
Affordable,Intelligent Digital Eyewear
Overview of Innovation:
Eye Hyper Tracking System - Smart Wearable
Viewpointsystem has developed a completely new system to measure and understand human perception through the eyes.
The Eye Hyper Tracking doesn't just capture the line of sight,but also how the person reacts to what is seen. The system in the form of smart lightweight safety rated glasses allows extremely precise measuring of observations and insights coupled with the ability to SHARE what is being seen via REMOTE LIVE STREAMING.
  • Telemedicine - A health professional can conduct or instruct a procedure with the aid of a precise hands free view.
  • Training - Any aspect of training can be covered, be it a live event or with the ability to record 'what is seen' it can be then shared, learned from and shown as a unique prespective into the instructor or wearers' viewpoint and preception
  • Paramedic / 1st Responder - Imagine a world where an expert can see what you are looking at and give you on the spot support. Envisage a paramedic or 1st responder calling in advance to show the recieving hospital the extent or seriousness of a situation
  • Improving Results - Instructions are often given and confirmed as being understood, communication is key in getting things right first time. With a view of 'how' to carry out a instruction, in certain circumstances a person viewing your first attempt is both supportive and safe.
  • Reducing Costs - Specialists cannot be everywhere all of the time. With a live streaming function, they are only ever a click away to see what you see, thus reducing the need to travel, rebook appointments, move from place to place.
The system has truely endless possibilites. Having been in the scientific arena for a number of years it is proven to be relaible and very accurate. Our system takes the technology from the lab into the real world, being light, highly mobile and robust it is user friendly, simple and smart.

The revolution in the measurement and interpretation of human perception has truly begun.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption
Benefit to NHS:
NHS Benefits
  • Efficiency - Simulation of scenarios for training
  • Efficiency - Centrally situated teams all viewing the same situation though the same perspective
  • Efficiency - 1st Responder / Paramedic support given, time saved when arrival at hospital, faster turnaround times
  • Efficiency - Right 1st time approach to training, supportive and inclusive
  • Efficiency - Faster turnaround times for paramedics at hospitals
  • Cost Benefit - Travel of key staff and personnel
  • Cost Benefit - Training budgets reduced to all areas
  • Cost Benefit - Specialists can support remotely, no need to always attend sites
  • Cost Benefit - Abilty to simulate a scenario or situation. Feedback could be given by instructor remotely
  • Cost Benefit - General hospital infastructure - The system is applicable to services outside of medical arena - IT support, Machinery supplier support, building support.
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
The system is designed to support all industries with medical being a specific area.
Our system not only enables faster, safer, most cost efficent ways of doing things, it provides an enabler to reduce time and improve effectivness.
Any improvements or cost savings can only help improve patient or colleagues healthcare, reduce waiting lists and improve services. It is also key to ensure the highly trained dedicated staff have every possible piece of equipment to help improve their working life balance and conditions.
Current and planned activity: 
Our current status is to engage with all 15 AHSN's in the UK.
Our system was only launched in UK in Sept 2016, and we have only just started to engage with the UK health sector.
We have a number of doctors, paramedics and hospitals trialing our system in Europe, and we have just engaged with a leading surgeon in USA who is keen to try our technology, as he was the first surgeon to use Google Glasses to carry out a live stream procedure.

Our primary intention is to be seen and heard by the NHS. We are keen to visit and demonstrate the system and possibilites first hand, as we are not a concept as we have an actual fully functioning system ready to use.
What is the intellectual property status of your innovation?:
We have IP on certain elements of the system.
Eye tracking is commonly adopted in VR/AR system is various guises.
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Read more
Hide details
Graham German 23/02/2017 - 13:14 Publish 1 comment
5
1
Votes
-99999
Innovation 'Elevator Pitch':
Aptvision is revolutionary to the radiology sector providing a paperless & cost effective workflow.  Designed with radiology experts, practiced in-depth and customised to meet the specific needs of today’s modern & demanding radiology environment.
Overview of Innovation:
Total Radiology Solution including RIS and other innovative solutions has been designed to increase efficiency in hospitals and clinics - not just to store patients’ data. It’s unique innovation can be seen in:
  • Cost savings and increased productivity
  • Increase revenues for hospitals and clinics: web booking, schedule optimisation
  • Reduce errors and staff duties
 
Aptvision RIS is the most innovative RIS on the market offering fully paperless workflow from start to finish: eReferral letters automatically attached to the RIS, e-consent forms, Online Results, etc. Aptvision RIS also assures:
  • Electronic access to all documentation and forms
  • Quick access to all medical history
  • Fully web based, no installation - just the web browser
  • Ability to report on studies from any location without a need of installing dedicated software on individual doctor’s PC.
 
Much more than a standard RIS, Total Radiology Solution offers:
  • Fully integrated Web Booking in which patients can book their appointment like a seat on an airplane. From the clinic’s website patients can see which appointments are available for the type of exam they need and book it immediately.
  • Aptvision’s system automatically provides a call back from a clinic’s Call Centre, to verify the selected appointment and go through safety questions. The operator is prompted by the system to ask the appropriate questions.
  • This feature has reduced the 40% dropped calls rate to zero and practically eradicated no shows and errors.
  • Before the appointment, the patient receives a SMS Reminder of their visit and gains access to the Online Consent Form. They can complete it on their phone or computer before their visit day.
  • On the appointment day, patients can use Online Registration in the clinic using the interactive kiosk or tablet & without the need to stand in a long queue at the reception. They can also monitor their live updated waiting time on dedicated monitors.
  • The electronic consent form as well as all previous medical history is attached to patient’s record in Total Radiology System leading to completely Paperless Workflow. Once the appointment is completed, patient is informed with an SMS telling them their results are ready and can be viewed in the Online Results portal if this is appropriate.
  • Voice Recognition to more quickly create medical reports
  • Scan Audits to improve the quality of the reports and enable sharing of expertise.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
Revenues increase
  • Across 16 clinics in Ireland we have facilitated savings of up to €600,000 per clinic through reducing no-shows, errors and through modality optimisation
  • We have also increased revenues by €2.4 million in an 18-month period through web-booking and e-referrals
 
Efficiency increase and cost reduction
Through fully paperless workflow
  • An advanced, configurable, fully integrated e-referral platform feeding actual availability of modalities
  • E-referral letters automatically attached to the RIS, e-consent forms, Online Results, etc
  • Electronic access to all documentation and forms
  • Quick access to all medical history
  • ensure scan is possible and safe for patient (availability & safety questions)
Reduction of manual processes
  • Fully business rules driven without manual intervention
  • Built-in processes for auto scheduling and bulk appointment operations
  • No re-typing of information
  • No web booking missed
  • Medical call centre takes over all calls so reception could focus on patients and their needs
  • Interactive kiosks, tablets and monitors allow patients to register online without a need to come to reception
Improved Patient satisfaction
  • Reduced waiting times for scans and results
  • Ensures patients safety and enhances patient experience at all stages of their appointments (web booking, online forms and results, SMS notifications, online registration etc.)
 
Quality improvement
Peer review feature that allows anonymous review of radiology reports by random peer
 
Better hospital/clinic management
Live updated personalized dashboards for quicker decision making and detailed reporting: revenue reports, comprehensive operations reports, etc.
 
Savings in time
  • Quick system implementation - within few days, not months
  • Easy and intuitive up and running in 30 mins
  • Improvements visible from day one
 
Existing customers have reported statistics of:
  • Modalities capacity increase of 30%
  • 1 extra scan per hour
  • 10 more booking per day
  • Reduced reporting time 20min -> 4min
  • 50 reports per day vs 15
"Aptvision is revolutionary to the radiology sector and is the key to a paperless workflow. It improves daily operations and leads to quicker reporting times and early diagnosis. My experience suggests that Aptvision RIS increases a clinic's efficiency and bottom line from day one and has been the answer to our digital problem in one step."

Prof. Michael Maher
Consultant Radiologist, Cork University Hospital
Professor of Radiology, University College Cork
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
With rapidly increasing demand for diagnostic imaging and hospital and clinics workflow heavily relying on paper and manual duties radiology providers are sometimes unable to cope with that increased demand and provide their diagnostic in efficient and timely manner which can result in patient dissatisfaction and in some cases even lost lives.

Aptvision Total Radiology Solution offers a solution that can revolutionize radiology industry by promoting efficiency and paperless workflow that increases productivity in hospitals and clinic and ultimately benefits patients and their lives.
Our innovative features can benefit patients in numerous manner including:
  • Better and quicker access to radiology
     
  • Reduced waiting times for scans and results which can save lives
     
  • Ensures patients safety and enhances patient experience at all stages of their appointments (web booking, online forms and results, SMS notifications, online registration etc.)
     
  • Quality improvement - Peer review feature that allows anonymous review of radiology reports by random peer. It improves the quality of the reports, enhances share of expertise and allows discussion of interesting cases with experts in anonymous manner. This hugely benefits patients and again helps to save lives
     
  • Make use of modern ecommerce technologies to patients
Current and planned activity: 
Aptvision has just completed the Serendip programme.

We have applied for late inclusion into supplychain RIS/PACS frameworks.

We are actively engaging with Queen's hospital (BHR hospitals trust). We have presented the system and received a very positive response and we are currently organising a full day workshop with all staff.

We are presenting shortly to Black County Alliance.

We are seeking to work in partnership with an NHS Trust to deliver an early demonstrator for the NHS.
What is the intellectual property status of your innovation?:
Full intellectual property of all applications and solutions is owned by Aptvision Ltd.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
2
Read more
Hide details
Fiona Smith 14/02/2017 - 12:23 Publish Login or Register to post comments
6
2
Votes
-99999
Innovation 'Elevator Pitch':
Active+: Reducing demand for Outpatient Serivces with proactive education, activation and exercise using connected devices to self-care.
Overview of Innovation:
Active+ is an effective, evidence-based exercise class, supported by self-care technology, education and training, in a peer-to-peer supported programme developed in Huntingdonshire. The programme supports falls prevention (strength/ balance), cardiac, cancer and pulmonary rehabilitation.

In May 2017, the Activ8rlives Active+ feasibility began with cardiac rehabilitation classes inte-grating remote monitoring technology. These are being extended to people with coronary heart disease risk factors, cancer and chronic obstructive pulmonary disorder.

Active+ is a collaboration between local technology provider Aseptika Limited (Activ8rlives), Huntingdonshire District Council (HDC) Active Lifestyles, Papworth Hospital NHS Foundation Trust, Huntingdonshire Community Cancer Network (HCCN), Hunts Breathe for Life and Eastern Academic Health Science Network (EAHSN).

​See Maggie's story (Cardiac Rehabilitiation) here
​See Colin's story (Cancer Rehabilition - living with prostate cancer) here.

For further information contact
Kevin A. Auton, PhD, Managing Director, Aseptika Limited kevin.auton@aseptika.com www.activ8rlvies.com
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Active+ fills the gap between existing health and care services, with the intention of improving health outcomes and minimising expensive interventions resulting from deterioration. Evidence4 shows that people who are more activated are more likely to adopt positive behaviours and have clinical indicators within a normal range, resulting in 8% lower costs than those less activated in the fist year of support and 21% less in the second year.
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
Patients are educated and supported to interpret the data to enable improved understanding of their health status.
  1. Prevent unnecessary admissions as patients have access to 24/7 the COPD rapid response team as soon as there is any health deterioration for treatment to prevent unnecessary admission into hospital. The collected data is currently being analysed by Knowsley Respiratory Community Team.
  2. Technology improves patient’s confidence in managing their COPD. For patients who experience frequent infections and disease exacerbation, this can be a lifeline. In Liverpool 90% of participants would recommend to Friends and Family. 60% would be prepared to make a financial contribution of £300 to support costs.
Current and planned activity: 
Looking for Clinical Champions in Secondary Care seeking to reduce the Outpatient Workload by creation of an alternative step-down care pathway while still retaining connection with patients in a light-touch mode.
What is the intellectual property status of your innovation?:
IP owned by Aseptika Ltd.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
Kevin A. Auton 12/01/2017 - 12:55 Publish 1 comment
5
1
Votes
-99999

Recent Activities

Knowing Me! has been moved from Initial Submission to Publish 1 hour 37 min ago
Joanne Mewis commented on Hexitime- The Skill Exchange and Timebank for Improving Healthcare 1 day 21 hours ago
Hexitime- The Skill Exchange and Timebank for Improving Healthcare has been moved from Initial Submission to Publish 1 day 21 hours ago
Digital solution to create a whole school approach to mental health has been moved from Initial Submission to Publish 3 days 6 hours ago
emily rose voted on UroShield: A breakthrough in treating CAUTI 1 week 3 days ago

Active Campaigns